drugset / Trial / NCT03110107
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.
Timeline
- Start
- 2017-05-04
- Primary completion
- 2024-04-04
- Completion
- 2024-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986218 | Monoclonal antibody | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
Indications
No indication recorded.